Cas:84104-80-3 Wilforlide A acetate manufacturer & supplier

We serve Chemical Name:Wilforlide A acetate CAS:84104-80-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Wilforlide A acetate

Chemical Name:Wilforlide A acetate
CAS.NO:84104-80-3
Synonyms:Olean-12-en-29-one, 3-(acetyloxy)-22,29-epoxy-, (3β,22β)-;(3β,22β)-29-Oxo-22,29-epoxyolean-12-en-3-yl acetate
Molecular Formula:C32H48O4
Molecular Weight:496.721
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:565.3±50.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.551
PSA:52.60000
Exact Mass:496.355255
LogP:8.36

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Olean-12-en-29-one, 3-(acetyloxy)-22,29-epoxy-, (3β,22β)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(3β,22β)-29-Oxo-22,29-epoxyolean-12-en-3-yl acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Olean-12-en-29-one, 3-(acetyloxy)-22,29-epoxy-, (3β,22β)- Use and application,Olean-12-en-29-one, 3-(acetyloxy)-22,29-epoxy-, (3β,22β)- technical grade,usp/ep/jp grade.


Related News: The majority of adults with lupus have increased type I interferon signalling, which is known to be associated with disease activity and severity. Methylphosphonsaeure-chlorid-(3-(4-methoxy-phenyl)-ureid) manufacturers SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. diphenyl sulphone-2,4,4′-tricarboxylic acid suppliers The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. (R)-2-((E)-1-Methyl-propenyl)-cyclobutane-1,1-dicarboxylic acid diethyl ester vendor & factory.